Compare InMode Ltd (INMD) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs 22nd Century Group Inc — how do they compare? InMode Ltd trades at $14.2 (market cap $809.93M), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: InMode Ltd is far larger — about 1302.8× 22nd Century Group Inc's market cap, and InMode Ltd is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and 22nd Century Group Inc for 32 Days on average.
| INMD | XXII | |
|---|---|---|
Market Cap | $809.93M | $621.67K |
Volume | 365,490 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $16.62 | $483.00 |
52-Week Low | $12.76 | $0.80 |
Typical Hold Time | 28 Days | 32 Days |
Enterprise Value | $313.27M | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.20, up 1.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with 76.52% gross margins and 20.69% net income margin, though Q1 2026 earnings missed expectations. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share. Analyst consensus is divided with 45% buy ratings amid ongoing shareholder activism concerns.
The stock presents value opportunity with attractive valuation multiples (P/E 11.63, EV/EBITDA 4.48) but faces near-term execution risks. Key catalysts include Q3 earnings delivery and resolution of acquisition talks, while risks involve management credibility and competitive pressures in aesthetic medicine markets.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
